Efficacy of Baricitinib in Patients with Refractory Adult-Onset Still’s Disease
暂无分享,去创建一个
[1] T. Sugiyama,et al. Latent class analysis of 216 patients with adult-onset Still’s disease , 2022, Arthritis Research & Therapy.
[2] K. Migita,et al. Interferon-γ induces interleukin-6 production by neutrophils via the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway , 2021, BMC Research Notes.
[3] P. Hur,et al. Adult-onset Still's disease in focus: Clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies. , 2021, Seminars in arthritis and rheumatism.
[4] K. Nichols,et al. Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome , 2021, Frontiers in Pharmacology.
[5] P. Través,et al. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib , 2021, Annals of the Rheumatic Diseases.
[6] K. Nichols,et al. Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis , 2021, Frontiers in Immunology.
[7] M. Dougados,et al. Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study , 2020, Rheumatology.
[8] M. Buch,et al. Mixed results with baricitinib in biological-resistant adult-onset Still’s disease and undifferentiated systemic autoinflammatory disease , 2020, RMD Open.
[9] A. Risitano,et al. Ruxolitinib for steroid-resistant acute GVHD. , 2020, Blood.
[10] S. Ye,et al. Macrophage activation syndrome associated with adult-onset Still’s disease: a multicenter retrospective analysis , 2020, Clinical Rheumatology.
[11] Liyan Wan,et al. Tofacitinib in refractory adult-onset Still’s disease: 14 cases from a single centre in China , 2020, Annals of the Rheumatic Diseases.
[12] S. Ibrahim,et al. Racial/Ethnic variations in morbidity and mortality in Adult Onset Still's Disease: An analysis of national dataset. , 2019, Seminars in arthritis and rheumatism.
[13] Y. Pers,et al. Treatment of refractory adult onset Still's disease with combination anakinra and baricitinib therapy. , 2019, Rheumatology.
[14] T. Barnetche,et al. Adult-onset Still’s disease biological treatment strategy may depend on the phenotypic dichotomy , 2019, Arthritis Research & Therapy.
[15] O. Silvennoinen,et al. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases , 2019, BioDrugs.
[16] E. Feist,et al. Mechanisms, biomarkers and targets for adult-onset Still’s disease , 2018, Nature Reviews Rheumatology.
[17] B. Fautrel,et al. New Markers for Adult-Onset Still's Disease. , 2017, Joint, bone, spine : revue du rhumatisme.
[18] Chengde Yang,et al. A Pilot Study on Tocilizumab for Treating Refractory Adult-Onset Still’s Disease , 2017, Scientific Reports.
[19] J. Dipersio,et al. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial , 2017, Journal of Hematology & Oncology.
[20] A. Fischer,et al. Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice. , 2016, Blood.
[21] M. González-Gay,et al. Adult-onset Still's disease: Advances in the treatment. , 2016, Best practice & research. Clinical rheumatology.
[22] T. Sumida,et al. Nationwide epidemiological survey of 169 patients with adult Still's disease in Japan , 2015, Modern rheumatology.
[23] F. Martinon,et al. Pathogenesis of adult-onset Still’s disease: new insights from the juvenile counterpart , 2014, Immunologic Research.
[24] P. Sève,et al. Adult-onset Still's disease. , 2014, Autoimmunity reviews.
[25] T. Kishimoto,et al. Longterm Safety and Effectiveness of the Anti-interleukin 6 Receptor Monoclonal Antibody Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis in Japan , 2014, The Journal of Rheumatology.
[26] H. Lévesque,et al. Reactive macrophage activation syndrome possibly triggered by canakinumab in a patient with adult-onset Still's disease. , 2013, Joint, bone, spine : revue du rhumatisme.
[27] A. Mimori,et al. Benefit and a possible risk of tocilizumab therapy for adult-onset Still’s disease accompanied by macrophage-activation syndrome , 2011, Modern rheumatology.
[28] J. Sibilia,et al. Tocilizumab in refractory adult Still's disease , 2011, Arthritis care & research.
[29] M. Schiller,et al. Clinical Manifestations but not Cytokine Profiles Differentiate Adult-onset Still’s Disease and Sepsis , 2010, The Journal of Rheumatology.
[30] E. Baldissera,et al. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still's disease. , 2010, Arthritis and rheumatism.
[31] M. Inanç,et al. Adult‐onset still's disease , 2009, International journal of clinical practice.
[32] M. Kurrer,et al. Retinal microangiopathy and rapidly fatal cerebral edema in a patient with adult‐onset Still's disease and concurrent macrophage activation syndrome , 2008, American journal of hematology/oncology.
[33] G. Cook,et al. Primer: inflammasomes and interleukin 1β in inflammatory disorders , 2008, Nature Clinical Practice Rheumatology.
[34] C. Dinarello,et al. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. , 2005, Arthritis and rheumatism.
[35] A. Tamakoshi,et al. Estimated prevalence and incidence of adult Still's disease: findings by a nationwide epidemiological survey in Japan. , 1997, Journal of epidemiology.
[36] G. Still,et al. On a Form of Chronic Joint Disease in Children. , 1978, Medico-chirurgical transactions.